Dow Jones

39 806,77

-0,49%

DAX

Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Aravive (delisted) (VSAR)
Aravive (delisted) (VSAR) Actualités

VSAR

VERSARTIS, INC. (VSAR)

Aravive (delisted)

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:VSAR

1 2 3 4 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
19/10/2018	22h14	Edgar (US Regulatory)	Statement of Beneficial Ownership (sc 13d)	NASDAQ:VSAR	Aravive (delisted)
17/10/2018	12h04	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:VSAR	Aravive (delisted)
17/10/2018	00h34	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:VSAR	Aravive (delisted)
17/10/2018	00h07	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:VSAR	Aravive (delisted)
16/10/2018	23h07	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:VSAR	Aravive (delisted)
15/10/2018	13h00	GlobeNewswire Inc.	Aravive Biologics and Versartis Complete Merger	NASDAQ:VSAR	Aravive (delisted)
05/10/2018	22h47	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:VSAR	Aravive (delisted)
20/09/2018	23h05	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:VSAR	Aravive (delisted)
06/09/2018	22h22	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:VSAR	Aravive (delisted)
06/09/2018	15h27	Edgar (US Regulatory)	Confidential Treatment Order (ct Order)	NASDAQ:VSAR	Aravive (delisted)
06/09/2018	12h01	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:VSAR	Aravive (delisted)
04/09/2018	13h04	Edgar (US Regulatory)	Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)	NASDAQ:VSAR	Aravive (delisted)
08/08/2018	22h25	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:VSAR	Aravive (delisted)
08/08/2018	22h16	Edgar (US Regulatory)	Amended Current Report Filing (8-k/a)	NASDAQ:VSAR	Aravive (delisted)
07/08/2018	22h15	GlobeNewswire Inc.	Versartis Reports Second Quarter 2018 Financial Results and Reviews Recent Developments	NASDAQ:VSAR	Aravive (delisted)
03/08/2018	23h58	Edgar (US Regulatory)	Securities Registration: Business Combination (s-4)	NASDAQ:VSAR	Aravive (delisted)
24/07/2018	22h15	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:VSAR	Aravive (delisted)
10/07/2018	14h29	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:VSAR	Aravive (delisted)
04/06/2018	14h00	GlobeNewswire Inc.	Versartis Enters into Merger Agreement with Aravive Biologics to Form a Clinical-Stage Biopharmaceutical Company Advancing In...	NASDAQ:VSAR	Aravive (delisted)
08/05/2018	22h15	GlobeNewswire Inc.	Versartis Reports First Quarter 2018 Financial Results	NASDAQ:VSAR	Aravive (delisted)
11/04/2018	12h06	Edgar (US Regulatory)	Amended Annual Report (10-k/a)	NASDAQ:VSAR	Aravive (delisted)
26/03/2018	22h05	GlobeNewswire Inc.	Eyenovia Appoints Three Industry Veterans to Board of Directors	NASDAQ:VSAR	Aravive (delisted)
06/03/2018	23h29	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:VSAR	Aravive (delisted)
01/03/2018	22h05	GlobeNewswire Inc.	Versartis Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update	NASDAQ:VSAR	Aravive (delisted)
30/11/2017	14h00	GlobeNewswire Inc.	Report: Exploring Fundamental Drivers Behind Amerco, Caesars Entertainment, Air Products and Chemicals, Consolidated Edison, ...	NASDAQ:VSAR	Aravive (delisted)
26/10/2017	22h05	GlobeNewswire Inc.	Versartis Reports Third Quarter 2017 Financial Results and Provides Corporate Update	NASDAQ:VSAR	Aravive (delisted)
26/10/2017	22h05	GlobeNewswire Inc.	Versartis Hires Cowen to Assist in Evaluating Potential Strategic Transactions	NASDAQ:VSAR	Aravive (delisted)
21/09/2017	22h30	GlobeNewswire Inc.	Versartis Announces Phase 3 VELOCITY Trial of Somavaratan in Pediatric Growth Hormone Deficiency Did Not Meet Primary Endpoin...	NASDAQ:VSAR	Aravive (delisted)
07/09/2017	22h05	GlobeNewswire Inc.	Versartis’ Twice-Monthly Somavaratan for Pediatric Growth Hormone Deficiency to be Featured in Oral and Poster Presentation...	NASDAQ:VSAR	Aravive (delisted)
05/09/2017	22h05	GlobeNewswire Inc.	Versartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, M...	NASDAQ:VSAR	Aravive (delisted)